Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on November 7, 2024. The filing reports a corporate event regarding the presentation of clinical data at an upcoming industry conference.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific operational event rather than financial performance.
Material Changes
There are no material financial changes reported in this document. The primary event is the announcement that the company will present clinical data from its ongoing Phase 1b clinical trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, TX, from November 8-10, 2024.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard context of clinical trial data presentation. The press release detailing the clinical data is attached as Exhibit 99.1.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific details on the Phase 1b clinical trial data.
- Verify the dates and location of the 39th Annual Meeting of the Society for Immunotherapy of Cancer (November 8-10, 2024, Houston, TX).
- Monitor subsequent filings for any updates on the clinical trial results following the conference presentation.